NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

Aktis Oncology AKTS

Aktis Oncology listed on Nasdaq on 9 Jan 2026 and is not in the S&P 500. It is worth $915 million. Its price history starts on 9 Jan 2026. Its board has 9 directors, 6 of them independent. 4 other officers are on file. At 30 Jun 2026, Mpm Bioimpact was its largest institutional holder, with 8.8% of the company.

CEO
Matthew Roden
Chair
Todd Foley
Listed
9 Jan 2026 on Nasdaq, IPO filings and terms
Headquarters
Boston, MA
Market cap
$915M
19 Nov 2026 close
Revenue
-
No annual report yet

Financials

Financial history

Twelve months to 30 Sep 2026, from Aktis Oncology's quarterly filings.

Quarters since Mar 2025

P/E
-
No profit over the last four quarters

Quarterly results

Each quarter's revenue, net income and free cash flow.

Mar 2025 to Sep 2026

$0$1M$2M$3M$4M20252026$4M

Aktis Oncology's market cap since January 2026

Weekly, up to 13 Nov 2026

Mar 2026MayJulSepNov$930M

Board and leadership

Board and officers

Board from the proxy filed 30 Mar 2026; officers filed up to 30 Sep 2026

NameTitleSinceIndependentCommitteesAge
Directors (9)
Todd FoleyChairNot independent 路 since 2020 路 Compensation (chair), Nominating and Corporate Governance (chair)Managing Director, MPM BioImpact LLCChair2020NoCompensation (chair), Nominating and Corporate Governance (chair)54
Matthew RodenPresident and CEONot independent 路 since 2020President and CEO2020No55
Glenn GormleyDirectorDirector
Ken HerrmannDirectorIndependent 路 since 2024 路 Nominating and Corporate GovernanceDirector and Chair of the Department of Nuclear Medicine, Universit盲tsmedizin EssenDirector2024YesNominating and Corporate Governance48
Helen Susan KimDirectorIndependent 路 since 2021 路 Nominating and Corporate GovernanceSenior Managing Director, Vida Ventures, LLCOther boards: Prothena Corporation plcDirector2021YesNominating and Corporate Governance63
Oleg NodelmanDirectorIndependent 路 since 2021Founder and Portfolio Manager, EcoR1 Capital, LLCOther boards: AnaptysBio, Galapagos NV and ZymeworksDirector2021Yes49
Lloyd Mitchell SegalDirectorIndependent 路 since 2021 路 Audit, Nominating and Corporate GovernanceCo-founder, Repare Therapeutics, Inc.Director2021YesAudit, Nominating and Corporate Governance62
Michael A. ShermanDirectorIndependent 路 since 2025 路 Audit, CompensationDirector, Werewolf Therapeutics, Inc.Other boards: Werewolf TherapeuticsDirector2025YesAudit, Compensation59
Mary ThistleDirectorIndependent 路 since 2025 路 Audit (chair), CompensationFormer Special Advisor, Bill & Melinda Gates Medical Research InstituteOther boards: Cullinan Therapeutics, Q32 Bio, Entrada Therapeutics and Vigil NeuroscienceDirector2025YesAudit (chair), Compensation66
Officers (4)
Kyle D. KuvalankaChief Financial OfficerLast filed 8 Jan 2026Chief Financial Officer
Akos CzibereChief Medical OfficerLast filed 24 Sep 2026Chief Medical Officer
Paul L. FeldmanChief Scientific OfficerLast filed 8 Jan 2026Chief Scientific Officer
Shulamit Ron-BiggerChief Operating OfficerLast filed 10 Jul 2026Chief Operating Officer

Owners and trading

Largest institutional holders

Each fund group's share of Aktis Oncology. Where a company has several share classes, the share is of its total value.

13F filings for the quarter to 30 Jun 2026

These five hold 32.2% of Aktis Oncology.

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers sold $3.2 million of stock in 5 sales and bought $59.2 million in 3 purchases in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
23 Sep 2026SaleAkos CzibereChief Medical OfficerChief Medical OfficerSale12,500$259K
20 Jul 2026SaleKen HerrmannDirectorDirectorSale4,856$119K
17 Jul 2026SaleKen HerrmannDirectorDirectorSale3,065$77K
8 Jul 2026SaleAkos CzibereChief Medical OfficerChief Medical OfficerSale50,000$1.4M
8 Jul 2026SaleShulamit Ron-BiggerChief Operating OfficerChief Operating OfficerSale50,000$1.4M
12 Jan 2026BuyOleg NodelmanDirectorDirectorBuy2,222,222$40M
12 Jan 2026BuyHelen Susan KimDirectorDirectorBuy835,000$15M
12 Jan 2026BuyTodd FoleyChairChairBuy232,870$4.2M

Timeline

Leadership changes, layoffs and insider sales

20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025

2 departures and 1 appointment of directors and officers and 2 large insider sales in the last two years.

Left the company or board 2Appointed 1WARN layoff notices 0Large insider sales 2Jan 2025AprJulOctJan 2026AprJulOct

Insider sales of $1 million or more, and the largest tenth of Aktis Oncology's insider sales.

Events, newest first

Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet and no earnings release figures from the last six months.